Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Yervoy
Pharma
With ODAC, FDA weighs limiting PD-1 drugs in stomach cancer
Existing approvals for BMS and Merck meds will play into the discussions, and BeiGene's two open applications for Tevimbra will face scrutiny.
Angus Liu
Aug 22, 2024 3:28pm
ASCO: Bristol calls Roche and AZ's bets in 1L liver cancer
Jun 4, 2024 8:00am
ASCO: BMS' triplet, Iovance's Amtagvi-Keytruda target melanoma
May 23, 2024 5:00pm
Bristol Myers fails to beat AZ in stage 3 lung cancer
May 13, 2024 10:23am
BMS shoots for 1L liver cancer again with Opdivo, Yervoy combo
Mar 20, 2024 10:18am
BMS shows I-O duo's power in first-line colorectal cancer
Jan 20, 2024 10:00am
